DNA robot inflicts fatal blow on cancer cells

SCIENTISTS have created a robot made from DNA that can be instructed to find diseased cells in the body and deliver a payload to kill or reprogram them, according to a study from Harvard University.

The robot was made by folding DNA strands into a shape roughly like a clamshell. The researchers programmed the nano-sized device to open in the presence of leukaemia and lymphoma cells in a laboratory dish, where they delivered immune system antibodies that caused the cells to self-destruct, according to a report in the journal Science.

The next step will be to test the system in animals, tweaking the robot so it can circulate longer to locate all cancer cells. The technology isn't ready for commercial use, said Shawn Douglas, an author of the study.

Advertisement: Story continues below

''In diseases such as cancer we know if we can find every single last cell and kill or reprogram it, we can cure that disease,'' said Dr Douglas, a researcher at the Wyss Institute for Biologically Inspired Engineering at Harvard, in Boston. ''A lot of our current therapies fall short.''

The idea is based on the behaviour of the body's immune cells, which recognise viruses or other invaders and attack them, Dr Douglas said. The DNA nano-robots, with similar capabilities, may potentially lead to the development of new types of targeted cancer treatments that kill only abnormal cells, he said.

The robots don't reproduce. They have to be built in a process that has gained traction since the idea of DNA nanotechnology was first suggested in 1982.

DNA is a material, shaped in the form of a revolving ladder, that carries the genetic information in our cells. The double-sided strands have so-called sticky ends that allow them to be joined with other DNA. Scientists, led by Nadrian Seeman, now head of the department of chemistry at New York University, have used those sticky ends to form DNA into lattices that can be shaped.

The latest research created a robot in a clamshell shape that's held together with a ''zipper'' made of a special sequence of DNA, the report said. The zipper was programmed to release its grip when it recognised specific targets on a cell, allowing the robot to release its payload.

Dr Douglas and fellow scientists used the robot to deliver instructions encoded in antibodies to the cancer cells.

''It's an important step forward in specific targeting,'' said Milan Stojanovic, an assistant professor of experimental therapeutics at Columbia University, New York, who wasn't involved in the research. ''It looks exciting.''

Besides cancer, the robots may also benefit people with autoimmune disease, Dr Douglas said.

BLOOMBERG

Read the original:
DNA robot inflicts fatal blow on cancer cells

Posted in DNA

DNA nanorobot triggers targeted therapeutic responses

ScienceDaily (Feb. 16, 2012) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a robotic device made from DNA that could potentially seek out specific cell targets within a complex mixture of cell types and deliver important molecular instructions, such as telling cancer cells to self-destruct. Inspired by the mechanics of the body's own immune system, the technology might one day be used to program immune responses to treat various diseases.

The research findings recently appear in the journal Science.

Using the DNA origami method, in which complex three-dimensional shapes and objects are constructed by folding strands of DNA, Shawn Douglas, Ph.D., a Wyss Technology Development Fellow, and Ido Bachelet, Ph.D., a former Wyss Postdoctoral Fellow who is now an Assistant Professor in the Faculty of Life Sciences and the Nano-Center at Bar-Ilan University in Israel, created a nanosized robot in the form of an open barrel whose two halves are connected by a hinge. The DNA barrel, which acts as a container, is held shut by special DNA latches that can recognize and seek out combinations of cell-surface proteins, including disease markers. When the latches find their targets, they reconfigure, causing the two halves of the barrel to swing open and expose its contents, or payload. The container can hold various types of payloads, including specific molecules with encoded instructions that can interact with specific cell surface signaling receptors.

Douglas and Bachelet used this system to deliver instructions, which were encoded in antibody fragments, to two different types of cancer cells -- leukemia and lymphoma. In each case, the message to the cell was to activate its "suicide switch" -- a standard feature that allows aging or abnormal cells to be eliminated. And since leukemia and lymphoma cells speak different languages, the messages were written in different antibody combinations.

This programmable nanotherapeutic approach was modeled on the body's own immune system in which white blood cells patrol the bloodstream for any signs of trouble. These infection fighters are able to home in on specific cells in distress, bind to them, and transmit comprehensible signals to them to self-destruct. The DNA nanorobot emulates this level of specificity through the use of modular components in which different hinges and molecular messages can be switched in and out of the underlying delivery system, much as different engines and tires can be placed on the same chassis. The programmable power of this type of modularity means the system has the potential to one day be used to treat a variety of diseases.

"We can finally integrate sensing and logical computing functions via complex, yet predictable, nanostructures -- some of the first hybrids of structural DNA, antibodies, aptamers and metal atomic clusters -- aimed at useful, very specific targeting of human cancers and T-cells," said George Church, Ph.D., a Wyss core faculty member and Professor of Genetics at Harvard Medical School, who is Principal Investigator on the project. Because DNA is a natural biocompatible and biodegradable material, DNA nanotechnology is widely recognized for its potential as a delivery mechanism for drugs and molecular signals. But there have been significant challenges to its implementation, such as what type of structure to create; how to open, close, and reopen that structure to insert, transport, and deliver a payload; and how to program this type of nanoscale robot.

By combining several novel elements for the first time, the new system represents a significant advance in overcoming these implementation obstacles. For instance, because the barrel-shaped structure has no top or bottom lids, the payloads can be loaded from the side in a single step--without having to open the structure first and then reclose it. Also, while other systems use release mechanisms that respond to DNA or RNA, the novel mechanism used here responds to proteins, which are more commonly found on cell surfaces and are largely responsible for transmembrane signaling in cells. Finally, this is the first DNA-origami-based system that uses antibody fragments to convey molecular messages -- a feature that offers a controlled and programmable way to replicate an immune response or develop new types of targeted therapies.

"This work represents a major breakthrough in the field of nanobiotechnology as it demonstrates the ability to leverage recent advances in the field of DNA origami pioneered by researchers around the world, including the Wyss Institute's own William Shih, to meet a real-world challenge, namely killing cancer cells with high specificity," said Wyss Institute Founding Director, Donald Ingber, M.D., Ph.D. Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Children's Hospital Boston, and Professor of Bioengineering at Harvard's School of Engineering and Applied Sciences. "This focus on translating technologies from the laboratory into transformative products and therapies is what the Wyss Institute is all about."

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Wyss Institute for Biologically Inspired Engineering at Harvard.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

S. M. Douglas, I. Bachelet, G. M. Church. A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads. Science, 2012; 335 (6070): 831 DOI: 10.1126/science.1214081

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

View post:
DNA nanorobot triggers targeted therapeutic responses

Posted in DNA

DNA matches Houston man to 2009 rape

A Houston man faces charges of rape and robbery in a 2009 case after a DNA test identified him as a suspect.

James West Jorden, 26, who is wanted on a charge of aggravated sexual assault, was not in custody Friday, according to online law enforcement records.

A woman told Houston police that she went to an apartment in the 6900 block of the South Loop East on July 5, 2009, to visit a friend.

As she walked through the complex, a man that she had never seen before pushed her into a vacant apartment, where he pulled her to the ground by her hair, according to court documents.

The man, later identified as Jorden through a DNA match, got on top of her and forced her to remove her pants and panties as he punched her several times in the head, records state.

After raping her, the man demanded her money, according to a complaint against Jorden filed by the Harris County District Attorney's Office. The woman pulled $190 from her clothing and threw it at the man, the complaint states.

As he was picking up the money, the woman ran to her car and drove to Ben Taub General Hospital, where she was examined for rape and gave a report to police, records state.

Last month, the state crime laboratory in Austin reported that a sample from the woman's rape kit matched Jorden's DNA. On Jan. 26, the woman tentatively identified him as her assailant in a photo line-up, police said.

carol.christian@chron.com

Read the original post:
DNA matches Houston man to 2009 rape

Posted in DNA

Scientific American Publisher Launches $49 Online Textbook

The publisher of Scientific American and Nature is stepping into a new genre with its first digital textbook, the company announced on Thursday.

Principles of Biology, already in use at three California State universities, is a web-based introductory text. At $49, it costs about three times less than its typical paper counterpart.

[More from Mashable: Inkling Takes on Apple iBooks With a New Tool for Publishers]

It stands out from both Nature Publishing's collection of scientific journals and magazines, as well as from similarly priced digital textbooks.

Publishing Director Vikram Savkar, who left Pearson to head up Nature Publishing's new Nature Education division in 2007, says the publisher's goal is to make high-quality original science textbooks that incorporate its large library of scientific research. Whereas most publishers convert their traditional books to digital ones through a third-party book maker, Nature Publishing built its first textbook to be digital.

[More from Mashable: Apple Announces a New iPad Textbook Experience]

"Ebooks have always been about putting a pdf of traditional books online," he says of other digital textbook makers, which include companies such as Kno, Chegg and CourseSmart. "What we’ve developed is a textbook. It’s not a reader, we're a publisher."

The book includes text and diagrams one would expect from any version of a biology text as well as data sets and research articles from the publisher's archive. Nature Publishing hired about 75 experts to contribute "modules" that can easily be reordered by teachers rather than chronological chapters.

There are a few features that aren't typical of digital textbooks, such as questions that test comprehension throughout the text and a quiz at the end of each chapter that can help teachers understand class progress. But basically, Principles of Biology is just a book.

What Nature Publishing has managed to do, however, is make it a very practical book. Because it's web-based, it can be accessed on any device with a browser. It's cheap. It can be arranged to fit the syllabus of individual teachers. And Nature Education can update its web-based pages in a jiffy if, say, someone figures out how to decode the human genome halfway through the semester.

Image courtesy of iStockphoto, atreides64

This story originally published on Mashable here.

Follow this link:
Scientific American Publisher Launches $49 Online Textbook

Grey's Anatomy-Private Practice Crossover Scoop: The Shepherd Siblings Reunite Again!

The bad news: Erica, who had a child with Private Practice's Cooper, has a terminal brain tumor. The good news: Amelia Shepherd and her big brother Derek will reunite to try to save her.

Amelia (Caterina Scorsone) will travel to Grey's Anatomy's Seattle Grace during a special crossover episode, airing Thursday at 9/8c, in which she'll convince Derek (Patrick Dempsey) to lend a hand in saving Erica (A.J. Langer) - something that has thus far seemed impossible.

Grey's Anatomy's Sandra Oh: Cristina and Owen head to couples therapy!

"We're coming at the case from such a place of hopelessness in terms of Erica's prognosis, that it can only go up from here," Scorsone tells TVGuide.com. "There's pressure for Amelia to do the best job possible, but Erica is going to die, that's the hard reality that everyone's been dealing with for this whole story arc, so even the fact that there's a possibility that she could live is something better than what we had thought an episode [ago]."

Erica has long resisted the idea of treatment, fearing it would limit her time with her son Mason (Griffin Gluck). And it isn't foolproof: The difficult procedure requires the surgeons to remove the tumor in less than 90 seconds. "It really is a dangerous procedure that they're attempting to do, so Erica's quite shaken by how immediate the option is," Scorsone says. "She has to decide within a very short amount of time, and if it doesn't go well, that's going to be the last time she sees her son, so that's a huge decision for anyone."

Exclusive: Paul Adelstein to direct an episode of Private Practice

"Once she's there, and she's presented with what the procedure would actually entail and how risky it is, and it almost sounds impossible, she has even more reservations about it," adds Paul Adelstein. "The biggest challenge of all to Erica is that she still hasn't told Mason."

Erica's case will also mark the first time the Shepherd siblings have been together since Amelia's recent trip to rehab. Though Derek was missing from Amelia's big intervention earlier this season on Private, her falling off the wagon will be addressed during the crossover. "He's the one who brings it up," Scorsone says. "Families are complicated and there's a lot of history between the two of them. They've shared good times and bad, but ultimately, they have a bit of a confrontation about it, but it's resolved in an interesting and positive way."

Don't expect Amelia, who ventured to Seattle Grace last season, to make some of the same mistakes again - like sleeping with Mark Sloan (Eric Dane). "There's no time for dilly-dallying," she jokes. "Amelia has lives to save!"

The Grey's Anatomy-Private Practice crossover begins at 9/8c on ABC.

View original Grey's Anatomy-Private Practice Crossover Scoop: The Shepherd Siblings Reunite Again! at TVGuide.com

Related Articles on TVGuide.com

Other Links From TVGuide.com

View the original article on TVGuide.com

See the rest here:
Grey's Anatomy-Private Practice Crossover Scoop: The Shepherd Siblings Reunite Again!

Histogenics to Present at 7th Annual New York Stem Cell Summit

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit http://www.histogenics.com.

Read the rest here:
Histogenics to Present at 7th Annual New York Stem Cell Summit

Wray Herbert: The Physiology of Willpower: Where Does Discipline Come From?

Willpower is the key to much that's good in life. Willpower is what makes us save for the future rather than splurge now. It helps us to keep our heads down, studying and working when we really don't feel like it, to earn that degree or promotion. Willpower allows us to say no to that tempting cigarette, extra dessert, or second glass of whiskey -- and to hop on the treadmill. And, of course, failures of self-control can sabotage all those goals.

So it's no wonder that psychological scientists have been studying willpower for decades, trying to figure out who is disciplined under what circumstances -- and why. What exactly is going on in the mind's cognitive machinery -- and the brain's neurons -- when we successfully summon our will -- or when we say, oh the hell with it?

One of the reigning theories of willpower is what's called the energy model of self-control. According to this model, the brain is like a muscle, with a limited supply of strength, which can be depleted through exertion. Nobody is disciplined all the time; we all have lapses. And according to the energy model, these lapses occur when one act of self-control weakens our resolve, leaving us "fatigued" as we face another challenge. Many studies have demonstrated that an act of mental exertion can compromise subsequent acts of discipline. What's more, proponents of this theory have reported evidence that the brain -- again like a muscle -- is fueled primarily by simple carbohydrates, like sugar, and that depleted willpower can be replenished simply by refueling.

This model of self-control has been tremendously influential, but not all scientists are convinced it's the whole story. Northwestern University's Daniel Molden is among the skeptics. He and a team of colleagues have been using new laboratory methods and novel experimental designs to reexamine the role of carbohydrate metabolism in self-discipline -- and to offer a competing theory of how willpower plays out in the brain.

The scientists question several aspects of the energy model, beginning with the fundamental assertion that acts of self-control lower blood glucose levels. They suspected that this important finding might be the result of using imprecise blood glucose monitors, so they reran the basic experiment using state-of-the-art laboratory measures. They recruited volunteers, who fasted and rested before having their baseline blood glucose level measured. Some of the volunteers then completed a vigilance task requiring high self-control, while others did a task requiring little mental discipline. Afterward, all the volunteers gave blood samples for further analysis, and also performed another self-control challenge.

The results were intriguing. Volunteers who initially completed the mentally challenging task were in fact less persistent on the subsequent task. This is consistent with earlier work supporting the energy model. But -- the more important finding -- these volunteers did not show a drop in blood glucose, indicating that the act of willpower did not lead to increased carbohydrate metabolism, as the model predicts. Nor does it appear that low blood sugar can explain the subsequent lapse in mental power.

The energy model also predicts that consuming sugar will refuel self-control, by reversing the depletion of mental resources needed for discipline. Molden and colleagues reexamined this core idea in an imaginative way: As before, some of the volunteers performed a mentally depleting self-control task, and others did not. Then, some rinsed their mouths out with a solution of water and table sugar, spitting it out as they would with any mouthwash. Others rinsed with a solution that was sweetened with Equal, so it seemed just like a sugary drink but contained no fuel. Immediately after rinsing, all the volunteers attempted a second task requiring persistence and self-control.

The results again challenged the energy model. As reported in a forthcoming issue of the journal Psychological Science, those who rinsed with the artificially sweetened drink were much less persistent -- consistent with the idea that self-control is mentally depleting. However, rinsing with the sugary solution appeared to restore the volunteers' lost willpower -- significantly more than rinsing with the artificially sweetened drink. The rinse is crucial here, and a departure from the original lab work: In the earlier experiments that led to the energy model, the volunteers had to actually ingest the sugar to get mentally replenished. But this study showed that merely rinsing with the sugary mouthwash had the same effect, restoring self-discipline. What's more, it had this effect immediately. The experiment allowed no time to metabolize the sugar and make it into brain fuel.

So what's happening here? If mental exertion is not depleting blood sugar, but is compromising subsequent self-discipline, then what's the mechanism? And what's restoring self-control, if not metabolized carbs? The scientists believe the mechanism is motivation. They believe that the mouth "senses" the carbohydrates in the mouthwash, and this sensation signals -- likely through the brain's dopamine system -- the possibility that a reward is coming. Sensing that an energy boost is coming, the brain is motivated to put in extra effort. In short, the sugar motivates -- rather than fuels -- willpower.

The scientists ran two different versions of the rinsing experiment. One demonstrated the effect of the mouthwash on physical persistence; the other on cognitive persistence. But one important question remained unanswered: Is it possible that even rinsing one's mouth with sugar might boost blood glucose -- drawing out the body's supplies? If so, this would revise -- but support -- the energy model of self-control. To address this, the scientists directly tested the effect of carbohydrate rinsing on blood glucose levels. They had a group of volunteers rinse repeatedly with a carbohydrate solution that was much stronger than the usual rinse -- to make the standard of proof as rigorous as possible. Others drank the same concentrated solution. The results gave further support to the new motivational model of self-control. Blood glucose levels jumped in those who drank the sugary drink, but didn't budge for those who rinsed.

All this may sound like inside-the-laboratory hair splitting, but it's not. Understanding the nitty-gritty of how willpower works has wide-ranging social implications. If sugar and metabolism do play an important role in boosting self-control, educators would want to think about the kinds of cafeteria foods that might optimize discipline, productivity and learning in the classroom. And how should society deal with metabolic deficiencies, if in fact they pose greater challenges, for some, to success and well-being? Or alternatively, if lack of self-control is really a lack of motivation, rather than energy or ability, and motivation can be restored with something as simple as a mouthwash, this opens all sorts of possibilities for novel interventions in the future.

For more by Wray Herbert, click here.

For more on emotional intelligence, click here.

 

 

 

Follow Wray Herbert on Twitter: http://www.twitter.com/wrayherbert

Excerpt from:
Wray Herbert: The Physiology of Willpower: Where Does Discipline Come From?

Study show nutrition labels make some food less healthy

  To view our videos, you need to
enable JavaScript. Learn how.
install Adobe Flash 9 or above. Install now.

Then come back here and refresh the page.

DURHAM — It has been nearly two decades since companies began placing nutrition information on their products, letting consumers know what they are eating.

Researchers from Duke University's Fuqua School of Business studied the nutrition level of food products before and after the nutrition labeling regulations began in the early 1990's. Findings show found food products sold in supermarkets decreased in nutrition, but increased in taste.

"If the first ingredient is corn syrup, it's not coming home," said Raleigh resident Elizabeth Upchurch.

Researchers believe many consumers prefer tasty food and companies want to stay competitive; which may mean adding fats or sugars to their products.

"Although firms had to disclose nutrition facts to consumers, they had no requirement to improve the nutrition of their products,” said Duke University professor of business Christine Moorman. “So just because regulation is present, doesn't mean consumers should not be vigilant."

The study shows some benefits since labeling began. Smaller companies have improved their nutrition levels. Findings also show nutrition labels improved the quality of junk food and food that is eaten in small portions, such as peanut butter.

See the original post here:
Study show nutrition labels make some food less healthy

Innovation in the Health and Nutrition Industry — 2012 NutrAward Voting Now Open

BOULDER, Colo., Feb. 17, 2012 /PRNewswire/ -- Voting is now open for the 2012 NutrAward at http://www.nutraward.com.  The 2012 NutrAward will be presented to the companies with the best new functional ingredient and best new finished product, awarded on Thursday, March 8, 2012 at the Nutracon conference.

The 2012 finalists are:

Best New Ingredient:
Lalmin® VitaD® by Lallemand Health Ingredients
Quatrefolic® by Gnosis S.p.A
Tocomin SupraBio® by Carotech Inc.
Zychrome™ by InterHealth Nutraceuticals

Best New Finished Product:
CocoaWell True Energy by Reserveage Organics
Fruitasia by Protica Research
Portobello Mushroom Powder by Dole Nutrition Institute
ProbioKid® Vita+ by Institut Rosell Lallemand

The finalists have been selected based on how well the ingredient or product meets the defined criteria, which includes:

Best New Ingredient category:

Scientific Merit Efficacy Market Potential Safety Innovation Ability to Increase Market Credibility Introduced from Jan 2010 to present

Best New Finished Product Category:

Viable Product Emerging Category Creative Product Concept Distinct Health Application Unique Packaging Matchless Marketing Introduced from Jan 2010 to present

The NutrAward winner will be selected based on a weighted vote by the selection committee, consisting of a panel of industry experts, scientists and nutritionists, as well as by cumulative votes of registered Nutracon and Engredea attendees.

2011 NutrAward Winners

The 2011 Best New Ingredient NutrAward was awarded to DSM Nutritional Products Inc. for Fruitflow®, a natural, water-soluble tomato-based concentrate contributing to healthy blood flow.  The 2011 Best New Finished Product was awarded to Ganeden for Good Cacao™ an organic superfood chocolate.

For more information on Nutracon and the NutrAward and to vote, visit http://www.nutraconference.com.   You must be a registered Nutracon or Engredea attendee to vote.  Register today at http://www.engredea.com/register or http://www.nutraconference.com/register.

Nutracon is the premier education and networking conference for the health and nutrition industry. The conference provides relevant insights for innovation based on science and technology, case studies and market

The trade show for the global supply market, Engredea showcases new ingredients, technologies, applications and services for healthy foods-and-beverages, dietary supplement/bioactive and nutricosmetic markets. Engredea is co-located with Natural Products Expo West and the Nutracon Conference.

About New Hope Natural Media

New Hope Natural Media (www.newhope.com) is the leading media resource and information provider for the natural, organic and healthy products industry, with print, in-person/event, and e-business products and services. Penton Media (www.penton.com) is the largest independent business-to-business media company in the U.S., serving more than 6 million business professionals every month.  

Contact: Heather Smith
(303) 998 – 9232
hsmith@newhope.com

Link:
Innovation in the Health and Nutrition Industry -- 2012 NutrAward Voting Now Open

Aegon Profit Falls on Charges; Shares Rise on Longevity Swap

February 17, 2012, 5:44 PM EST

By Maud van Gaal

(Updates to add longevity swap and analyst comments, starting in third paragraph.)

Feb. 17 (Bloomberg) -- Aegon NV, the Dutch owner of U.S. insurer Transamerica Corp., reported a 75 percent decline in fourth-quarter profit on reorganization costs and lower investment returns from equity markets and interest rates.

Net income fell to 79 million euros ($106 million) from 318 million euros a year earlier, the Hague-based insurer said today. The firm had 194 million euros in charges, including 48 million euros related to U.K. insurance policies.

The shares rose as the insurer said it completed a swap with Deutsche Bank AG to protect the firm against the risk of pensioners living longer than expected. Aegon, which makes most of its profit in the U.S., repeated that it aims to increase underlying pretax profit by 7 percent to 10 percent a year on average until 2015 and to post a return on equity of 10 percent to 12 percent.

“It’s positive that longevity risk has been reduced in the Dutch book,” Albert Ploegh, an Amsterdam-based analyst at ING Groep NV, wrote in a note today. “After several insurers had to take charges on the back of increased longevity, Aegon now appears to have tackled this issue.”

Shares of Aegon, whose Pyramid building is a landmark in San Francisco’s financial district, jumped as much as 7 percent in Amsterdam today. They were up 6.3 percent to 3.97 euros at 11:50 a.m. local time, giving the company a market value of 7.6 billion euros. That outpaced the 1.1 percent advance in the 28- company Bloomberg Europe 500 Insurance Index.

No Acquisitions

Aegon doesn’t plan a share buyback or acquisitions at this point, Chief Executive Officer Alex Wynaendts told analysts on a conference call today. He plans to continue a strategy of maintaining a strong capital position as market volatility will likely persist in coming years, even as the “bottom of the euro crisis is probably behind us.”

Profit missed the average estimate of 209 million euros in a Bloomberg survey of 10 analysts. Aegon said today it proposed a 2011 dividend of 10 cents per share, as the company had previously indicated. It would be the company’s first payout since 2008, when it took state aid during the financial crisis.

“The fourth-quarter result was mainly affected by one-off charges which we do not expect to occur in 2012,” Lemer Salah, an Amsterdam-based analyst at SNS Securities, said in a note. “We believe that the company is well positioned to achieve its objectives in the U.S. and Netherlands.”

Longevity Swap

Wynaendts said Aegon may do more transactions like today’s longevity swap, which will see Deutsche Bank protect 12 billion euros, or one-third of the reserves in the Dutch business. “The transaction reduces required capital at an attractive cost,” Aegon said.

The risk of pensioners living longer will be borne by investors rather than Deutsche Bank, the German bank said in a separate statement. It is the first transaction to place such risk wholly in the capital markets, it said.

In 2011, Aegon set aside 82 million euros to cover life- expectancy risks in the Netherlands, Wynaendts said in an interview today. The transaction today helps the insurer increase its capacity on the Dutch pension market.

Aegon’s value of new business, a measure of projected future profitability of new policies, fell 59 percent to 53 million euros in the fourth quarter. That is unsurprising given “the historic low interest rates” in the insurer’s key markets, Wynaendts told reporters on the call.

U.K., Dutch Charges

Underlying pretax profit, which excludes investment swings, fell 23 percent to 346 million euros, almost matching the average estimate of 347 million euros in a Bloomberg survey of 12 analysts. Earnings on this basis fell 17 percent in 2011.

In the Netherlands, Aegon wrote down 75 million euros on its distribution business in anticipation of a ban on commissions in life and pension products starting in 2013, Wynaendts said. The U.K. charges, which were related to fixing administrative errors, exceeded the estimate of Cor Kluis, an analyst at Rabobank International.

“With all these charges for the U.K. taken, the year 2012 should be a normal profit level,” Kluis, based in Utrecht, the Netherlands, said in a note.

Aegon’s profit goals rely on assumptions including a 4.75 percent U.S. 10-year bond yield for 2016, which is more than double the current 2 percent rate.

The U.S. Federal Reserve said last month that it sees “exceptionally low” interest rates through 2014, having previously pledged to refrain from raising borrowing costs until at least the middle of 2013. Insurers suffer from lower long- term interest rates as they hold back returns from bond investments and increase future liabilities.

--With assistance from Martijn van der Starre in Amsterdam and Kevin Crowley in London. Editors: Keith Campbell, Steve Bailey.

To contact the reporter on this story: Maud van Gaal in Amsterdam at mvangaal@bloomberg.net

To contact the editor responsible for this story: Frank Connelly at fconnelly@bloomberg.net

Read the original here:
Aegon Profit Falls on Charges; Shares Rise on Longevity Swap

Better Control for DNA-Based Computations

Newswise — A North Carolina State University chemist has found a way to give DNA-based computing better control over logic operations. His work could lead to interfacing DNA-based computing with traditional silicon-based computing.

The idea of using DNA molecules – the material genes are made of – to perform computations is not new; scientists have been working on it for over a decade. DNA has the ability to store much more data than conventional silicon-based computers, as well as the potential to perform calculations in a biological environment – inside a live cell, for example. But while the technology holds much promise, it is still limited in terms of the ability to control when and where particular computations occur.

Dr. Alex Deiters, associate professor of chemistry at NC State, developed a method for controlling a logic gate within a DNA-based computing system. Logic gates are the means by which computers “compute,” as sets of them are combined in different ways to enable the computer to ultimately perform tasks like addition or subtraction. In DNA computing, these gates are created by combinations of different strands of DNA, rather than by a series of transistors. The drawback is that DNA computation events normally take place in a test tube, where the sequence of computation events cannot be easily controlled with spatial and temporal resolution. So while DNA logic gates can and do work, no one can tell them when or where to work, making it difficult to create sequences of computational events.

In a paper published in the Journal of the American Chemical Society, Deiters addressed the control problem by making portions of the input strands of DNA logic gates photoactivatable, or controllable by ultraviolet (UV) light. The process is known as photocaging. Deiters successfully photocaged several different nucleotides on a DNA logic gate known as an AND gate. When UV light was applied to the gate, it was activated and completed its computational event, showing that photoactivatable logic gates offer an effective solution to the “when and where” issues of DNA-based logic gate control.

Deiters hopes that using light to control DNA logic gates will give researchers the ability not only to create more complicated, sequential DNA computations, but also to create interfaces between silicon and DNA-based computers.

“Since the DNA gates are activated by light, it should be possible to trigger a DNA computation event by converting electrical impulses from a silicon-based computer into light, allowing the interaction of electrical circuits and biological systems,” Deiters says. “Being able to control these DNA events both temporally and spatially gives us a variety of new ways to program DNA computers.”

Note to editors: An abstract of the paper follows.

“DNA Computation: A Photochemically Controlled AND Gate”

Authors: Alex Prokup, James Hemphill, and Alexander Deiters, North Carolina State University
Published: Online in the Journal of the American Chemical Society

Abstract:
DNA computation is an emerging field that enables the assembly of complex circuits based on defined DNA logic gates. DNA-based logic gates have previously been operated through purely chemical means, controlling logic operations through DNA strands or other biomolecules. Although gates can operate through this manner, it limits temporal and spatial control of DNA-based logic operations. A photochemically controlled AND gate was developed through the incorporation of caged thymidine nucleotides into a DNA-based logic gate. By using light as the logic inputs, both spatial control and temporal control were achieved. In addition, design rules for light-regulated DNA logic gates were derived. A step-response, which can be found in a controller, was demonstrated. Photochemical inputs close the gap between DNA computation and silicon-based electrical circuitry, since light waves can be directly converted into electrical output signals and vice versa. This connection is important for the further development of an interface between DNA logic gates and electronic devices, enabling the connection of biological systems with electrical circuits.

Comment/Share

See original here:
Better Control for DNA-Based Computations

Posted in DNA

Bacteria, biology and bytes, oh my!

Sarah Bleau

Sarah Bleau is a news reporter with FOX 31 News

Science projects from Southwest Georgia students were on display at Darton on Friday  / Sarah Bleau

Nearly 200 science experiments by regional middle school and high school students were judged for a place in the state science fair

Read more: Local, State, Education, Science, News, Darton College’S Regional Science Fair, Georgia Science and Engineering Fair, International Science and Engineering Fair, Middle School Students, High School Students, Science Projects, Science Experiments, Albany Ga, Darton College

ALBANY, GA -- Middle school and high school students from across Southwest Georgia competed for a spot in the state science fair.

Nearly 200 students displayed their science projects at Darton College’s 40th Annual Regional Science Fair. Divisions for their experiments included computer science, animal sciences and biology.

The top exhibits received awards and invitations to compete at the 64th Georgia Science and Engineering Fair in Athens. Those who do well there go on to the Intel International Science and Engineering Fair in Pennsylvania.

Comments are the sole responsibility of the person posting them; they are not reflective of the views or opinions of Barrington Broadcasting, Fox 31, its directors or employees. If you believe a comment violates the Barrington Terms of Use, please flag it below.

Read this article:
Bacteria, biology and bytes, oh my!

James E. Marshall OCD Foundation Presents $225k to Johns Hopkins at 8th Annual Beyond Beauty Gala

NEW YORK, Feb. 17, 2012 (GLOBE NEWSWIRE) -- The James E. Marshall Obsessive Compulsive Disorder Foundation today announced it has presented Dr. Gerald Nestadt, director of the Johns Hopkins Department of Psychiatry and Behavioral Science with a $225,000 donation to support genetic research relating to OCD. Hosted by Emmy Award-winning CBS reporter Dana Tyler in New York City, the Beyond Beauty Gala honored Jill Belasco, CEO of Maesa Group; Kaplow President and CEO, Liz Kaplow; and Caroline Pieper-Vogt of the Scent Marketing Institute for their leadership in spreading awareness of this debilitating disease. Actress Dendrie Taylor was the evening's guest speaker, and presenters included Art Spiro, executive vice president of Elizabeth Arden; Carlotta Jacobson, president of Cosmetic Executive Women; and Nancy Berger-Cardone, vice president and publisher at Marie Claire.

The James E. Marshall OCD Foundation was founded in 2003 by Elysee Scientific Cosmetics President Linda Marshall and her family, in memory of her son who battled the condition his entire life. "Few people understand how truly devastating OCD can be, for both the people who suffer from it and the families and friends who love them," says Linda Marshall. "People often hear about other diseases and conditions, however, many who suffer from OCD are too ashamed to bring attention to it."

Since its inception, the James E. Marshall OCD Foundation has raised more than $2 million for OCD research. Though it is listed as one of the top ten most disabling diseases by the National Institute of Mental Health, people with OCD often go several years without treatment. Through past research funds, Dr. Nestadt and his team have been able to isolate a gene that they believe attacks the white matter in the brain, leading to OCD. The Foundation hopes this vital discovery is a key step to finding a better way to manage, treat, and perhaps even prevent OCD.

Despite the strides that have been made, there is still a lot of work to be done to increase public awareness and financial support for OCD, which affects millions of Americans and costs upwards of $8 billion annually in direct and indirect medical costs. The James E. Marshall OCD Foundation is currently the only organization dedicated to raising funds for genetic research related to this debilitating disease.

For more information, please visit: http://www.cureocd.org

This information was brought to you by Cision http://www.cisionwire.com
http://www.cisionwire.com/kaplow-communications/r/james-e--marshall-ocd-foundation-presents--225k-to-johns-hopkins-at-8th-annual-beyond-beauty-gala,c9222197

The following pictures are available for download:

[Image] James E. Marshall OCD Foundation's 8th Annual "Beyond Beauty" Gala

Visit link:
James E. Marshall OCD Foundation Presents $225k to Johns Hopkins at 8th Annual Beyond Beauty Gala

Abattis Announces Launch of the World's First Painless Flu Shot

VANCOUVER, BRITISH COLUMBIA--(Marketwire -02/17/12)- Abattis Biologix Corporation (CNSX: FLU) (the "Company") is pleased to announce that it will sponsor and present in the 20th Annual Wellness Show, which will take place on 17, 18 & 19 of February, 2012 at the Vancouver Convention Center. Abattis will be present at booth #414/416 and will hold key presentations during this event including "Hot News for Cold Weather" presented by Dr. John Baumann, MD.

The Company also announces the launch of http://www.FastFluShot.com the world's first Painless Flu Shot. So unique, it has a US Patent titled "Method of preventing and treating avian influenza in humans".

This year marks the 20th year that health conscious people -- throughout North America and beyond - come to The Wellness Show to learn the most recent news on how to stay well. That's why Abattis Biologix, the Vancouver-based, up-and-coming Biotech Company, is proud to sponsor one of the most interesting workshops this year. No one will want to miss out on hearing the latest scientific evidence and nutritional findings about natural ways to enhance the body's natural defences, not only during the cold & flu season, but ALL year round! Medical Doctor, and Wellness specialist, Dr. John Baumann, MD, reveals it all.

In the presentation entitled "A Storm on the Horizon: How to Educate Our Immune System to Fight the Flu", Dr. Baumann will begin with a simple Q & A session with the audience on how the immune system works. During this workshop, all attendees will learn an impressive mix of basic immune system workings, along with the newest nutritional stars that shine for helping to teach our immune system how to be smart. More information can be found at the Sponsor's booth, #414/416.

Dr. Baumann states: "Typically, the human immune system vanquishes viral invaders, or neutralizes their ability to spread. In either case, the virus is eliminated from our body. This happens every day. But, some viruses are resistant to a strong immune system. The battle intensifies as a strong but unwise immune system escalates inflammation at the cost of healthy tissues. This creates a "Cytokine Storm" that can destroy our lungs - all from an immune system that is strong but not smart."

Given the time of year, this is the ideal time and place to come learn more about how to help yourself and your family stay healthy all year long.

Mike Withrow, CEO, states, "Abattis is moving forward on a targeted expansion path right now, and has many new products in development with plans for release in the near future. Our team of experts is sharply focused on creating additional unique formulations, with innovative delivery systems, in the areas of Anti Aging, Women's and Children's Health, Micro Nutrient Fortification, Cognitive Health, as well as Histamine and Anti-Inflammatory Solutions." For more information, visit http://www.fastflushot.com and call 1-888-538-6650.

About Dr. John Baumann

Dr. Baumann, with an MD from the Duke University School of Medicine, and a specialty in Internal Medicine from the University of Texas, has a very rich history. He has been a practicing Medical Doctor actively involved with innovative, successful patient care in hospitals and wellness clinics, an authority in natural medicines, as well as teaching and consulting for more than 30 years. Two of his claims to fame include his service as a Sports Medicine expert working with athletes: As the Medical Consultant to the San Francisco 49ers, and the prestigious position as Chief Medical Officer for the Santa Barbara, CA Olympic Village during the 1984 Olympics.

About Abattis Biologix Corporation

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

Yazan Al homsi, Director

Neither the CNSX nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

More here:
Abattis Announces Launch of the World's First Painless Flu Shot

World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

World Stem Cells, LLC Stem Cell Therapy at a state of the art clinic in beautiful Cancun. The clinic is staffed by top specialist in the field of stem cell implants and a new laboratory to support the stem cell treatments given.

(PRWEB) February 16, 2012

World Stem Cells, LLC. contract laboratory Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.) a new adult stem cell laboratory being built in Cancun, Mexico to support Stem Cell research, stem cell clinical trials and stem cell treatments. This was accomplished by private funding in conjunction with World Stem Cells, LLC worldstemcells.com a US patient management company, Medicina Biocelular Avanzada , S.E. de C.V. a Mexican patient management company and Advanced Cellular Medicine Clinic of Cancun, a Stem Cell treatment Clinic owned and operated by Dr. Sylvia M. Abblitt a well known board certified hematologist and oncologist, in Cancun.

Uniquely, Dr. Abblitt is one of a limited number of physicians licensed to perform autologous and allogeneic stem cell transplants. Dr. Abblitt has been utilizing stem cell therapies with successes for many years.

She is the president and lab director of Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.). Her extensive background includes having been the laboratory director and head of hematology for Hospital Fernando Quiroz for 11 years. As a pioneer in the stem cell transplant field, she brings a vast array of knowledge to the lab. Her memberships include the american association of blood banks (aabb), Mexican society of transfusional medicine, interamerica society of transfusional medicine, Mexican association) for studies of hematologyandicms and ICMS (international cellular medical society and all patients are monitored by ICMS an independent agency for a period of between 2-20 years on a quarterly basis. Dr. abblitt has had a 26-year clinical practice history.

The laboratory construction is complete and operations were transferred to our new facility. This facility provides Cancun, and patient around the world, a state of the art GLP laboratory to support their stem cell treatments in a beautiful, and positive environment. The lab was designed and constructed to provide one ISO7 lab, one wet lab along with a treatment area. This will allow stem cell retrieval, testing, culturing, selection, counting, analyses and sorting along with cryopreservation, without removal from the lab. This all in house capability reduces the possibility of contamination and errors. Dr. M. Abblitt will operate the Lab under cGMP/cGLP guidelines and use the state of the art facility to provide quality care to her stem cell transplant patients.

Working under the guidelines set forth by ICMS world stem cells, LLC ( http://worldstemcells.com/ ) provides stem cell treatment for ankylosing spondylitis, autism, cerebral palsy, charcot-marie-tooth disease (cmt), crohn’s diseases, copd, fuch’s disease, guillain-barre’ syndrome, hashimoto’s thryroiditis, itp, kidney diseases, macular degeneration, lupus (sle), multiple sclerosis, pad, parkinson’s disease, rheumatoid arthritis, scleroderma, stroke, ulcerative colitis

The laboratory will be engaged in private clinical trials, IRB’s and joint studies with US companies, Mexican Educational Institutes, US universities and doctors to better understand the benefits and precaution to be taken in the stem cell treatment process.

###

Charles Newcomer

727-421-4359
Email Information

More:
World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Pathfinder to Present at New York Stem Cell Summit

CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, will present at the 7th Annual New York Stem Cell Summit being held on Tuesday, February 21, 2012.

Event: 7th Annual New York Stem Cell Summit
Date: Tuesday, February 21, 2012
Place: Bridgewaters New York, 11 Fulton Street, New York, NY
Time: 3:35 pm ET

Dr. Franklin will be providing an overview of the Company's novel Pathfinder Cell therapy.

The New York Stem Cell Summit brings together stem cell company executives, researchers, investors and physicians to explore investment opportunities in stem cell research and innovation. More information can be found at http://www.stemcellsummit.com.

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. For more information please visit: http://www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

View post:
Pathfinder to Present at New York Stem Cell Summit

How (not) to think like a doctor

On our first day of physiology, our professor showed us a picture of an elephant. He let us look at it for several seconds and then asked: what is this? On the next slide, he put up a chest X-ray. We stared for a few more seconds and were then asked: what’s the diagnosis?

He was demonstrating what was done in a recent experiment that examined the way doctors think. In the study, similar images were shown for similarly brief amounts of time, but to physicians rather than first-year medical students. It took doctors the same amount of time to recognize an animal as to make a diagnosis – under 1.5 seconds. Moreover, brain scans revealed that the same parts of the brain were being used to do both tasks.

This was not the first time in medical school I was made acutely aware of how I think.

What are the ways a person could identify an elephant? One method is working from the top-down. You could observe: this is large, grey, and has four legs and a trunk. Then you would come up with possible objects that possess those qualities, exclude ones that do not make sense, and continue to collect and reason through data until you arrive at the correct diagnosis.

Or, you could reflexively recognize the pattern and make the identification.

For something like an elephant, which approach we take is obvious. We call upon pattern recognition all the time, without even consciously noticing that we’re solving a problem. It can be extremely beneficial.

Imagine if you had to derive an elephant from the top-down every time you saw one. Moreover, imagine you saw twenty elephants a day. You wouldn’t have the time to reason through your assortment of observations in each case. The ability to perceive patterns and instinctively classify them based on things we’ve seen before supplies us with the tools to derive those things we have not.

As a result, it makes sense that medicine would rely on this mode of thinking. Medicine is huge in scope. It is cumulative. Many doctors are taught the top-down approach – meaning take a few facts, and formulate a diagnosis. Receive a few pieces of the puzzle, and extrapolate the whole picture.

Entering medicine means learning a new language, and you won’t be able to solve complex problems if you are looking up every other word and puzzling through every concept in the question. There are undoubtedly disease patterns you should know, cold.

But there are downsides. Jump to conclusions based on only a few facts, and your ideas are prone to biases. There is the bias associated with arbitrary prior experience; you might be more likely to make a diagnosis of one illness, for instance, simply because you happened to see it before. You might try to massage your observations into preconceived models in which they do not belong. Or, you might discard stubborn data completely, assuming them flawed.

Maybe most of the time, your prediction based on pattern recognition will be correct. But you will be wrong about the complicated cases. And being wrong in medicine can have serious consequences.

Our professor’s point in showing us the elephant experiment was not to encourage us to think like the doctors in the study. Rather, the point was to show what we might be prone to do – and thereby to encourage us to resist those impulses. Do not guess, we were advised. Do not just memorize patterns. Work through each problem, and fill in each step.

Following these recommendations will be an uphill battle. Problem-solving takes time – something that is relentlessly lacking from medicine. Medicine is fast-paced. People talk fast and make decisions fast. The doctors in the study diagnosed chest X-ray lesions in a mere 1.33 seconds.

As I continue to learn more and find myself in increasingly fast-paced environments, I realize I may have the urge to memorize patterns. I can look at lab values and remember that the last time A and B went down, C and D went up, and feel tempted to speculate that the same disease process underlies a new case. I will likely have colleagues and superiors that endorse rather than temper this kind of thinking.

But medicine is more complicated than that.

I hope I can develop the ability to recognize the elephants of medicine when I need to, but to remember to pause and think: what else could be large, grey, with four legs and a trunk? What other information would I need to distinguish the possibilities?

Thinking like this will be more work. But it just might lead to discovering what’s really going on.

Image: From Wikimedia Commons

More here:
How (not) to think like a doctor

20 Minutes Of Exercise A Day Is Enough To Improve Your Health

1:00AM Today | Thorin Klosowski

It seems like one of the major reasons people don’t like to work out is the amount of time it takes to do so. However, a new study in the Journal of Physiology suggests you might be able to get all the exercise you need in just 20 minutes if you’re willing to work at it.

Photo by whologwhy.

We’ve talked briefly about interval training before, but this is one of the first studies to dig into if it actually works as a replacement for the usual recommendation of 30 minutes of continuous exercise. The idea is simple. You workout for one minute with strenuous activity and push your heart rate to about 90 per cent of its maximum rate. You can get a rough estimate of your heart rate by subtracting your age from 220. After the minute is up, you slow down and recover for one minute. You then repeat this 10 times for a total of 20 minutes (or 10 minutes of actual exercise). You can use this for running, cycling, swimming, or any number of cardiovascular workouts.

If you’re crunched for time and can’t get that full 30 minutes in, this is a great way to shorten the duration and still get in shape.

Physiological adaptations to low-volume, high-intensity interval training in health and disease [Journal of Physiology via New York Times]

Excerpt from:
20 Minutes Of Exercise A Day Is Enough To Improve Your Health

AMP presented testimony to the Patent and Trademark Office requesting moratorium on human gene patenting

AMP believes previous scientific and federal advisory committee publications, and the common knowledge of practitioners in the field, provide ample evidence for the patient harms and negative impact on testing associated with gene patents, and argue against human genes and genotype-phenotype associations as patentable subject matter. Further, AMP is also concerned that because the USPTO is not a healthcare focused agency it does not possess the needed expertise and resources to adequately assess the impact of patents on patients' ability to obtain confirmatory testing. For these reasons, AMP strongly urges the USPTO to base its assessment of the impact of gene patents on genetic testing on the report published by the Department of Health and Human Services (HHS) Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) published in April 2010 entitled, "Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests."

Ms. Williams explained, "This almost 400 page report represents approximately four years of active investigation and study and is an important reference on the subject. AMP encourages the USTPO to adopt the recommendations contained in the report."

"Patients are increasingly being harmed by patents that claim ownership over the biological relationships between genetic variants and clinical disease," stated Roger D. Klein, MD JD, Chair of AMP's Professional Relations Committee. For example, a method patent relating to a variation in a gene known as FLT3 that is used to qualify some leukemia patients for bone marrow transplant is forcing physicians and laboratories to split and geographically distribute irreplaceable bone marrow specimens. "Splitting samples not only creates an additional risk of specimen loss and delays the receipt of patient results," stated Dr. Klein, "it interferes with the ability of pathologists to provide synoptic interpretations involving multiple tests and prevents them from implementing cost saving algorithms that restrict testing to those tests that are truly necessary."

In light of the preceding, AMP asked the USPTO to place a moratorium on issuing gene patents. "By ceasing to grant gene patents, the USPTO would protect patients' access to high quality genetic testing until the issue receives full legal, legislative, and administrative consideration," said Ms. Williams.

Provided by Association for Molecular Pathology

See the original post here:
AMP presented testimony to the Patent and Trademark Office requesting moratorium on human gene patenting

AMP testifies at USPTO

Public release date: 16-Feb-2012
[ | E-mail | Share ]

Contact: Mary Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology

Alexandria, VA -- Today, the Association for Molecular Pathology (AMP) asked the U.S. Patent and Trademark Office (USPTO) to place a moratorium on the issuing of patents on human genes during testimony presented at an Agency hearing on genetic diagnostic testing. AMP is the lead plaintiff of 20 plaintiffs in an American Civil Liberties Union (ACLU) sponsored lawsuit challenging the validity of patents on two hereditary breast and ovarian cancer genes, BRCA1 and BRCA2. AMP joined the litigation because of its members' first hand view of the harmful effects of gene patents on patients with genetic diseases and their at-risk family members. "Every day, AMP members witness the ability of genetic testing to better patients' lives and improve their health. Unfortunately, they also experience firsthand the challenges imposed by gene patents that interfere with the practice of medicine and limit their treatment decisions," said Mary Williams, Executive Director of AMP.

AMP believes previous scientific and federal advisory committee publications, and the common knowledge of practitioners in the field, provide ample evidence for the patient harms and negative impact on testing associated with gene patents, and argue against human genes and genotype-phenotype associations as patentable subject matter. Further, AMP is also concerned that because the USPTO is not a healthcare focused agency it does not possess the needed expertise and resources to adequately assess the impact of patents on patients' ability to obtain confirmatory testing. For these reasons, AMP strongly urges the USPTO to base its assessment of the impact of gene patents on genetic testing on the report published by the Department of Health and Human Services (HHS) Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) published in April 2010 entitled, "Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests."

Ms. Williams explained, "This almost 400 page report represents approximately four years of active investigation and study and is an important reference on the subject. AMP encourages the USTPO to adopt the recommendations contained in the report."

"Patients are increasingly being harmed by patents that claim ownership over the biological relationships between genetic variants and clinical disease," stated Roger D. Klein, MD JD, Chair of AMP's Professional Relations Committee. For example, a method patent relating to a variation in a gene known as FLT3 that is used to qualify some leukemia patients for bone marrow transplant is forcing physicians and laboratories to split and geographically distribute irreplaceable bone marrow specimens. "Splitting samples not only creates an additional risk of specimen loss and delays the receipt of patient results," stated Dr. Klein, "it interferes with the ability of pathologists to provide synoptic interpretations involving multiple tests and prevents them from implementing cost saving algorithms that restrict testing to those tests that are truly necessary."

In light of the preceding, AMP asked the USPTO to place a moratorium on issuing gene patents. "By ceasing to grant gene patents, the USPTO would protect patients' access to high quality genetic testing until the issue receives full legal, legislative, and administrative consideration," said Ms. Williams.

###

ABOUT AMP:

The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. For more information, please visit http://www.amp.org.

CONTACT:

Mary Steele Williams
mwilliams@amp.org
301-634-7921


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

More:
AMP testifies at USPTO